41%) (2). The disease is rare before age 45 but incidence rises rapidly after that and peaks in the

selleck kinase inhibitor seventh decade of life. The major risk factors include smoking (3), hereditary predisposition to PaCa itself or to multiple cancers (4) and to a lesser degree, chronic pancreatitis (5). PaCa does not exhibit early symptoms and initial symptoms are often nonspecific. Classical presentation of PaCa (painless jaundice) is present in only 13-18% of the patients and is often accompanied by pruritus, acholic stools dark urine, and weight loss (6). Abdominal pain is present in 80-85% of patients with locally advanced or advanced disease. Acute pancreatitis and new onset diabetes mellitus Inhibitors,research,lifescience,medical can often be the initial presentations of PaCa (7),(8). In up to 75% of the cases, the tumor is located within pancreatic head mostly sparing the uncinate process.

Tumors in the pancreatic head often present early with biliary obstruction. However, tumors in the body and tail can remain asymptomatic till late in disease stage. Surgical resection is the standard of care for treatment Inhibitors,research,lifescience,medical but only but <10% of patients with pancreatic tumors have resectable tumors at the time of presentation. The criteria for unresectability include Inhibitors,research,lifescience,medical infiltration of superior mesenteric artery (SMA) and/or celiac artery or the presence of distant metastasis including metastatic celiac or mediastinal lymph nodes. The size of pancreatic tumor is a major determinant of resectability

and up to 83% of tumors ≤ 20 mm are resectable compared to only 7% of tumors > 30 mm in size (9). The 5 year survival rate in patients with resectable tumors can be as high as 20-25% and compares favorably with patients with unresectable tumor, very few of whom survive 5 years after diagnosis. Imaging Inhibitors,research,lifescience,medical techniques Inhibitors,research,lifescience,medical currently used for diagnosis and preoperative staging of pancreatic cancer include abdominal ultrasound (US), contrast-enhanced computed tomography(CT), magnetic resonance imaging (MRI), MR cholangiopancreatography (MRCP) and invasive imaging modalities like endoscopic retrograde cholangiopancreatography (ERCP) and endoscopic ultrasound (EUS). Imaging Modalities Abdominal Ultrasound (US) Abdominal ultrasound (US) is widely available, non-invasive, relatively inexpensive imaging modality without contrast associated adverse effects. It is usually performed to rule out choledocholithiasis and look for biliary dilation in patients Liothyronine Sodium who present with jaundice and abdominal pain. The real world accuracy of conventional US for diagnosing pancreatic tumors is 50 to 70% (10). The results of US are highly operator dependant. In addition, body habitus (adipose tissue), overlying bowel gas and patient discomfort can limit the use of US in evaluating the pancreas. If an initial US excludes choledocholithiasis in a patient with signs and symptoms to suggest a pancreatic etiology, CT or MRI is commonly used for further evaluation.